Literature DB >> 32083416

Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution.

Carlo A Bravi1,2, Giuseppe Rosiello3, Giuseppe Fallara3, Emily Vertosick4, Amy Tin4, Daniel Sjoberg4, Marco Bianchi3, Elio Mazzone3, Alberto Martini3, Paolo Dell'oglio3, Armando Stabile3, Giorgio Gandaglia3, Nicola Fossati3, Alberto Briganti3, Francesco Montorsi3, Andrew Vickers4.   

Abstract

BACKGROUND: To examine the predictive value of neutrophil-to-lymphocyte ratio in localized prostate cancer for surgical pathology and recurrence in patients treated by radical prostatectomy.
METHODS: We evaluated 1258 patients treated by radical prostatectomy at San Raffaele Hospital between 2011 and 2017 and assessed the association between preoperative neutrophil-to-lymphocyte ratio and surgical pathology (advanced stage, grade group ≥4, nodal involvement, grade discordance between biopsy and surgical pathology) and biochemical recurrence.
RESULTS: The preoperative neutrophil-to-lymphocyte ratio was not significantly associated with advanced stage (≥T3), International Society of Urological Pathology (ISUP) grade (≥4) or discordance. At multivariable analysis, patients with higher neutrophil-to-lymphocyte ratio had lower risk of nodal involvement at final pathology (odds ratio [OR]: 0.77; 95% confidence interval [CI]: 0.64, 0.92; P=0.005). The preoperative level of neutrophil-to-lymphocyte ratio was associated with biochemical recurrence on univariate analysis (OR: 0.81, 95% CI: 0.68, 0.96; P=0.017). Such a relationship was not significant at multivariable analysis adjusting for tumor severity (OR: 0.93, 95% CI: 0.79, 1.09; P=0.4).
CONCLUSIONS: Neutrophil-to-lymphocyte ratio does not have clinical utility for the prediction of adverse pathology and biochemical recurrence. Further research should focus on its value for predicting regional lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32083416      PMCID: PMC9514026          DOI: 10.23736/S2724-6051.20.03662-0

Source DB:  PubMed          Journal:  Minerva Urol Nephrol        ISSN: 2724-6051


  29 in total

1.  Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer.

Authors:  Armando Stabile; Fabio Muttin; Stefania Zamboni; Marco Moschini; Giorgio Gandaglia; Nicola Fossati; Paolo Dell'Oglio; Umberto Capitanio; Vito Cucchiara; Elio Mazzone; Carlo A Bravi; Vincenzo Mirone; Francesco Montorsi; Alberto Briganti
Journal:  Expert Rev Anticancer Ther       Date:  2019-08-30       Impact factor: 4.512

2.  Neutrophil-to-Lymphocyte Ratio Positively Correlates to Age in Healthy Population.

Authors:  Jian Li; Qingyu Chen; Xiaohong Luo; Jun Hong; Kunyi Pan; Xianghua Lin; Xiaoqiang Liu; Lijun Zhou; Han Wang; Ying Xu; Hongyu Li; Chaohui Duan
Journal:  J Clin Lab Anal       Date:  2014-10-02       Impact factor: 2.352

3.  Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy.

Authors:  Mehmet Özsoy; Marco Moschini; Harun Fajkovic; Francesco Soria; Christian Seitz; Tobias Klatte; Kilian Gust; Alberto Briganti; Pierre I Karakiewicz; Morgan Roupret; Gero Kramer; Shahrokh F Shariat
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-12-11       Impact factor: 5.554

4.  Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Authors:  Thomas Loubersac; Molière Nguile-Makao; Frédéric Pouliot; Vincent Fradet; Paul Toren
Journal:  Eur Urol Oncol       Date:  2019-01-31

5.  Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

Authors:  Giorgio Gandaglia; Nicola Fossati; Emanuele Zaffuto; Marco Bandini; Paolo Dell'Oglio; Carlo Andrea Bravi; Giuseppe Fallara; Francesco Pellegrino; Luigi Nocera; Pierre I Karakiewicz; Zhe Tian; Massimo Freschi; Rodolfo Montironi; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2017-04-12       Impact factor: 20.096

Review 6.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Authors:  Arnoud J Templeton; Mairéad G McNamara; Boštjan Šeruga; Francisco E Vera-Badillo; Priya Aneja; Alberto Ocaña; Raya Leibowitz-Amit; Guru Sonpavde; Jennifer J Knox; Ben Tran; Ian F Tannock; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2014-05-29       Impact factor: 13.506

7.  High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.

Authors:  Hakmin Lee; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee; Jong Jin Oh
Journal:  World J Urol       Date:  2015-10-08       Impact factor: 4.226

8.  Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.

Authors:  Young Suk Kwon; Christopher Sejong Han; Ji Woong Yu; Sinae Kim; Parth Modi; Rachel Davis; Ji Hae Park; Paul Lee; Yun-Sok Ha; Wun-Jae Kim; Isaac Yi Kim
Journal:  Clin Genitourin Cancer       Date:  2015-08-06       Impact factor: 2.872

Review 9.  Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jian Cao; Xuan Zhu; Xiaokun Zhao; Xue-Feng Li; Ran Xu
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

Review 10.  Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients.

Authors:  Xiaobin Gu; Xianshu Gao; Xiaoying Li; Xin Qi; Mingwei Ma; Shangbin Qin; Hao Yu; Shaoqian Sun; Dong Zhou; Wen Wang
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

View more
  1 in total

1.  The Clinical Utility of Systemic Immune-Inflammation Index Supporting Charlson Comorbidity Index and CAPRA-S Score in Determining Survival after Radical Prostatectomy-A Single Centre Study.

Authors:  Piotr Zapała; Karolina Garbas; Zbigniew Lewandowski; Łukasz Zapała; Aleksander Ślusarczyk; Cezary Ślusarczyk; Łukasz Mielczarek; Piotr Radziszewski
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.